Novartis Abstract re: Salmon Calcitonin and Osteoarthritis
"3-Month Treatment With Oral Salmon Calcitonin Suppresses Urinary Collagen Type II Degradation Products in Postmenopausal Women”
“Compared to placebo, the 1.0 mg daily group revealed the greatest decrease in urinary CTX-II after 3-month treatment (-19.7%, p=0.009).”
“Women receiving 1.0 mg of sCT also had the greatest reduction in 24-hours urinary CTX-I (-41.0%, pɘ.001) compared to women in placebo group.”
“Conclusion: Our study strongly suggests that this novel oral formulation of sCT may reduce cartilage degradation and thereby could provide therapeutic benefits for osteoarthritis. Women with higher cartilage turnover are more likely to benefit from sCT treatment. Further studies are warranted to address the effect of sCT at doses of 0.4 mg and 1.0 mg in patients with osteoarthritis.”
Presented at ACR/ARHP 68th Annual Scientific Meeting; Oct. 16-21, 2004, San Antonio, Texas